Crosses the blood-brain barrier to modulate appetite centers in the hypothalamus, reducing "food noise" and increasing.
Slows gastric emptying, ensuring nutrients are absorbed steadily and maintaining a prolonged state of physical satiety after smaller portions.
Enhances glucose-dependent insulin secretion and suppresses inappropriate glucagon release, stabilizing blood sugar throughout the day.
BMI of ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity.
Assessment of HbA1c, fasting insulin, and lipid panels to determine insulin resistance profiles.
Verification of no personal/family history of MTC or MEN 2 syndromes.
Comprehensive Metabolic Panel (CMP)
2.5mg Loading Phase. Focused on metabolic priming and receptor acclimation.
5mg - 7.5mg Transition. Appetite suppression becomes primary metabolic driver.
10mg - 15mg Target. Achieving peak lipolysis and metabolic reprogramming.
Bio-Individual Optimization. Stabilizing weight and hormonal balance for longevity.
